Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 210 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Morphine or Placebo Clear all
Completed Phase 3 Interventional

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
149
States / cities
Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 8, 2026, 9:09 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

NCT00505414
View directory record Official record
Conditions
Pain, Neoplasm, Cancer
Interventions
Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase, Tapentadol in the Maintenance Phase, Morphine in the Titration Phase
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
St. Petersburg, Florida • Elkhart, Indiana • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 4 Interventional Results available

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

NCT02600715
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions
Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna
Drug
Lead sponsor
Edgar LeClaire, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

NCT00226395
View directory record Official record
Conditions
Acute Pain
Interventions
Oxymorphone immediate release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 8, 2026, 9:09 AM EDT
Recruiting Phase 3 Interventional

Opioid-Sparing Joint Replacement

NCT07348627
View directory record Official record
Conditions
Pain Management, Opioid Consumption
Interventions
Placebo, Oxycodone 5 mg, Multimodal Non-Opioid Analgesia
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Not applicable Interventional Results available

Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function

NCT02469077
View directory record Official record
Conditions
Chronic Pain
Interventions
6 week aerobic exercise intervention, Placebo, Morphine, naloxone
Behavioral · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 8, 2026, 9:09 AM EDT
Terminated Phase 4 Interventional Results available

Low Pain Prediction in Cesarean Section Patients

NCT02143141
View directory record Official record
Conditions
Scheduled Cesarean Sections, Postoperative Pain Management, Side Effects
Interventions
duramorph, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

NCT01380093
View directory record Official record
Conditions
Nondependent Opioid Abuse, Episodic
Interventions
Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

NCT00661674
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Palonosetron, Hydroxyzine, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Chronic Low Back Pain Study

NCT01364922
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
hydrocodone/acetaminophen extended release, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
17
States / cities
Tucson, Arizona • Anaheim, California • Burbank, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 8, 2026, 9:09 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

NCT01681264
View directory record Official record
Conditions
Chronic Pain
Interventions
Morphine, Guanfacine 1mg, Guanfacine 2mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT01452529
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets, Placebo to match hydrocodone bitartrate q24h tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 4 Interventional Results available

Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors

NCT02351700
View directory record Official record
Conditions
Pituitary Tumor, Pain
Interventions
IV Caldolor, IV Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 79 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 8, 2026, 9:09 AM EDT
Active, not recruiting Phase 2 Interventional

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

NCT05463367
View directory record Official record
Conditions
Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 8, 2026, 9:09 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mechanisms of Hypoglycemia Associated Autonomic Failure

NCT00678145
View directory record Official record
Conditions
Diabetes Mellitus, Hypoglycemia, Autonomic Failure
Interventions
naloxone, fructose, exercise, Morphine sulfate, Epinephrine
Drug · Dietary Supplement · Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine

NCT01476124
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
morphine Placebo, GEn 600 mg, Morphine, GEn Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 8, 2026, 9:09 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT04926818
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 8, 2026, 9:09 AM EDT
Terminated Phase 1 Interventional

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

NCT06406400
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation

NCT05470465
View directory record Official record
Conditions
Hypercapnia, Ventilatory Depression
Interventions
Placebo and Oxycodone, Paroxetine and Oxycodone, Escitalopram and Oxycodone
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Early Phase 1 Interventional

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

NCT03845881
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Oxycodone, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

NCT04223609
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone, Placebo, EyeLink 1000 Plus, Oculo-Cognitive Addition test (OCAT), VT3mini - Eye Tracking Technology for OEMs
Drug · Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 59 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 8, 2026, 9:09 AM EDT
Suspended Phase 3 Interventional

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

NCT05324358
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine
Drug · Other
Lead sponsor
Neumentum, Inc.
Other
Eligibility
18 Years to 64 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 8, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

NCT03599089
View directory record Official record
Conditions
Post-surgical Pain
Interventions
CA-008, Placebo, Ketorolac, Acetaminophen, Oxycodone, Bupivacaine Hydrochloride
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Pasadena, California • Pasadena, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 8, 2026, 9:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Teriflunomide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 8, 2026, 9:09 AM EDT